T1	Participants 40 86	clozapine-treated patients with schizophrenia:
T2	Participants 384 432	in clozapine-treated patients with schizophrenia
T3	Participants 490 542	trial, clozapine-treated patients with schizophrenia
T4	Participants 902 908	eight.
T5	Participants 909 946	Nineteen patients completed the study
T6	Participants 1043 1101	the rosiglitazone group (n=9) and the placebo group (n=10)
T7	Participants 1322 1370	in clozapine-treated patients with schizophrenia
T8	Participants 1539 1569	in patients with schizophrenia
